Differential utilization and localization of ErbB receptor tyrosine kinases in skin compared to normal and malignant keratinocytes

被引:68
作者
Stoll, SW
Kansra, S
Peshick, S
Fry, DW
Leopold, WR
Wiesen, JF
Sibilia, M
Zhang, T
Werb, Z
Derynck, R
Wagner, EF
Elder, JT
机构
[1] Univ Michigan, Dept Dermatol, Med Ctr, Ann Arbor, MI 48109 USA
[2] Pfizer Global Res & Dev, Ann Arbor, MI USA
[3] Univ Calif San Francisco, Med Ctr, San Francisco, CA 94143 USA
[4] Inst Mol Pathol, A-1030 Vienna, Austria
[5] Univ Michigan, Med Ctr, Dept Radiat Oncol Canc Biol, Ann Arbor, MI USA
[6] Ann Arbor Vet Affairs Hlth Syst Hosp, Ann Arbor, MI USA
来源
NEOPLASIA | 2001年 / 3卷 / 04期
关键词
ErbB receptors; skin organ culture; keratinocytes; heparin-binding EGF-like growth factor; receptor tyrosine kinase;
D O I
10.1038/sj.neo.7900170
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Induction of heparin-binding epidermal growth factor-like growth factor (HB-EGF) mRNA in mouse skin organ culture was blocked by two pan-ErbB receptor tyrosine kinase (RTK) inhibitors but not by genetic ablation of ErbB1, suggesting involvement of multiple ErbB species in skin physiology. Human skin, cultured normal keratinocytes, and A431 skin carcinoma cells expressed ErbB1, ErbB2, and ErbB3, but not ErbB4. Skin and A431 cells expressed more ErbB3 than did keratinocytes. Despite strong expression of ErbB2 and ErbB3, heregulin was inactive In stimulating tyrosine phosphorylation in A431 cells. In contrast, it was highly active in MDA-MB-453 breast carcinoma cells. ErbB2 displayed punctate cytoplasmic staining in A431 and keratinocytes, compared to strong cell surface staining in MDA-MB-453. In skin, ErbB2 was cytoplasmic in basal keratinocytes, assuming a cell surface pattern in the upper suprabasal layers. In contrast, ErbB1 retained a cell surface distribution in all epidermal layers. Keratinocyte proliferation in culture was found to be ErbB1-RTK-dependent, using a selective inhibitor. These results suggest that in skin keratinocytes, ErbB2 transduces ligand-dependent differentiation signals, whereas ErbB1 transduces ligand-dependent proliferation/survival signals. Intracellular sequestration of ErbB2 may contribute to the malignant phenotype of A431 cells, by allowing them to respond to ErbB1 dependent growth/survival signals, while evading ErbB2-dependent differentiation signals.
引用
收藏
页码:339 / 350
页数:12
相关论文
共 72 条
[21]   A SPECIFIC INHIBITOR OF THE EPIDERMAL GROWTH-FACTOR RECEPTOR TYROSINE KINASE [J].
FRY, DW ;
KRAKER, AJ ;
MCMICHAEL, A ;
AMBROSO, LA ;
NELSON, JM ;
LEOPOLD, WR ;
CONNERS, RW ;
BRIDGES, AJ .
SCIENCE, 1994, 265 (5175) :1093-1095
[22]   Secondary dimerization between members of the epidermal growth factor receptor family [J].
Gamett, DC ;
Pearson, G ;
Cerione, RA ;
Friedberg, I .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (18) :12052-12056
[23]  
GENDIMENICO GJ, 1995, SKIN PHARMACOL, V8, P167
[24]   IN-VITRO CULTIVATION OF HUMAN TUMORS - ESTABLISHMENT OF CELL LINES DERIVED FROM A SERIES OF SOLID TUMORS [J].
GIARD, DJ ;
AARONSON, SA ;
TODARO, GJ ;
ARNSTEIN, P ;
KERSEY, JH ;
DOSIK, H ;
PARKS, WP .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1973, 51 (05) :1417-1423
[25]  
GILL GN, 1984, J BIOL CHEM, V259, P7755
[26]   ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling [J].
GrausPorta, D ;
Beerli, RR ;
Daly, JM ;
Hynes, NE .
EMBO JOURNAL, 1997, 16 (07) :1647-1655
[27]   INSECT CELL-EXPRESSED P180(ERBB3) POSSESSES AN IMPAIRED TYROSINE KINASE-ACTIVITY [J].
GUY, PM ;
PLATKO, JV ;
CANTLEY, LC ;
CERIONE, RA ;
CARRAWAY, KL .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (17) :8132-8136
[28]   Epidermal growth factor receptors: critical mediators of multiple receptor pathways [J].
Hackel, PO ;
Zwick, E ;
Prenzel, N ;
Ullrich, A .
CURRENT OPINION IN CELL BIOLOGY, 1999, 11 (02) :184-189
[29]  
Hansen LA, 2000, CANCER RES, V60, P3328
[30]   Neuregulin-4: a novel growth factor that acts through the ErbB-4 receptor tyrosine kinase [J].
Harari, D ;
Tzahar, E ;
Romano, J ;
Shelly, M ;
Pierce, JH ;
Andrews, GC ;
Yarden, Y .
ONCOGENE, 1999, 18 (17) :2681-2689